Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ultraviolet Therapy | 1 | 2020 | 1 | 0.660 |
Why?
|
| Keratitis | 1 | 2020 | 2 | 0.660 |
Why?
|
| Eye Infections, Bacterial | 1 | 2020 | 3 | 0.660 |
Why?
|
| Riboflavin | 1 | 2020 | 24 | 0.650 |
Why?
|
| Photosensitizing Agents | 1 | 2020 | 56 | 0.630 |
Why?
|
| Collagen | 1 | 2020 | 181 | 0.600 |
Why?
|
| Obesity | 6 | 2015 | 1151 | 0.520 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 125 | 0.490 |
Why?
|
| Cluster Analysis | 1 | 2016 | 207 | 0.490 |
Why?
|
| Risk Reduction Behavior | 3 | 2015 | 138 | 0.480 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 749 | 0.460 |
Why?
|
| Cyclooxygenase 2 | 2 | 2012 | 107 | 0.420 |
Why?
|
| Adenoma | 2 | 2012 | 96 | 0.400 |
Why?
|
| Colorectal Neoplasms | 3 | 2019 | 512 | 0.390 |
Why?
|
| Adenomatous Polyps | 1 | 2012 | 13 | 0.360 |
Why?
|
| Haplotypes | 2 | 2012 | 197 | 0.360 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 86 | 0.360 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2012 | 863 | 0.340 |
Why?
|
| Colonic Polyps | 1 | 2012 | 71 | 0.340 |
Why?
|
| Colonoscopy | 3 | 2019 | 122 | 0.330 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 9 | 0.320 |
Why?
|
| Tunica Media | 1 | 2009 | 15 | 0.320 |
Why?
|
| Patient Compliance | 3 | 2019 | 233 | 0.310 |
Why?
|
| Tunica Intima | 1 | 2009 | 22 | 0.310 |
Why?
|
| Brachial Artery | 1 | 2009 | 27 | 0.310 |
Why?
|
| Male | 38 | 2025 | 23409 | 0.310 |
Why?
|
| Humans | 48 | 2025 | 43102 | 0.310 |
Why?
|
| Alcoholism | 5 | 2014 | 305 | 0.300 |
Why?
|
| Middle Aged | 28 | 2019 | 12222 | 0.300 |
Why?
|
| Female | 36 | 2025 | 24698 | 0.290 |
Why?
|
| Blood Pressure | 3 | 2011 | 666 | 0.280 |
Why?
|
| Adult | 29 | 2025 | 13872 | 0.270 |
Why?
|
| Internship and Residency | 3 | 2015 | 146 | 0.270 |
Why?
|
| Research Subjects | 3 | 2021 | 35 | 0.270 |
Why?
|
| Regression Analysis | 5 | 2016 | 490 | 0.250 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 259 | 0.250 |
Why?
|
| Proglumide | 2 | 2022 | 3 | 0.230 |
Why?
|
| District of Columbia | 7 | 2019 | 80 | 0.230 |
Why?
|
| Sickle Cell Trait | 1 | 2025 | 19 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2019 | 989 | 0.220 |
Why?
|
| Exercise | 4 | 2016 | 692 | 0.220 |
Why?
|
| Body Mass Index | 5 | 2011 | 925 | 0.210 |
Why?
|
| Biomedical Research | 2 | 2022 | 502 | 0.210 |
Why?
|
| Aged | 18 | 2019 | 8214 | 0.210 |
Why?
|
| Endoscopy | 2 | 2014 | 17 | 0.200 |
Why?
|
| Appointments and Schedules | 2 | 2014 | 32 | 0.200 |
Why?
|
| Genetic Testing | 2 | 2014 | 91 | 0.190 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2025 | 193 | 0.190 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2022 | 66 | 0.180 |
Why?
|
| Hypertension | 3 | 2005 | 835 | 0.180 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2021 | 3 | 0.180 |
Why?
|
| Urinary Incontinence | 1 | 2021 | 15 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2016 | 734 | 0.170 |
Why?
|
| Attitude of Health Personnel | 3 | 2019 | 231 | 0.170 |
Why?
|
| Cognition | 3 | 2016 | 473 | 0.160 |
Why?
|
| Attitude to Health | 2 | 2014 | 338 | 0.160 |
Why?
|
| Anemia, Sickle Cell | 3 | 2007 | 187 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2018 | 863 | 0.160 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 2853 | 0.160 |
Why?
|
| Outpatients | 3 | 2019 | 37 | 0.160 |
Why?
|
| Visual Acuity | 1 | 2020 | 111 | 0.160 |
Why?
|
| Bacteria | 1 | 2022 | 293 | 0.140 |
Why?
|
| Ethanol | 2 | 2013 | 224 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 375 | 0.140 |
Why?
|
| Specialties, Surgical | 1 | 2018 | 7 | 0.140 |
Why?
|
| Life Style | 2 | 2015 | 334 | 0.140 |
Why?
|
| Patient Selection | 2 | 2021 | 205 | 0.140 |
Why?
|
| Risk Factors | 6 | 2025 | 3994 | 0.140 |
Why?
|
| Burnout, Professional | 1 | 2018 | 31 | 0.140 |
Why?
|
| Young Adult | 9 | 2015 | 5080 | 0.130 |
Why?
|
| Normal Distribution | 1 | 2016 | 14 | 0.130 |
Why?
|
| Poisson Distribution | 1 | 2016 | 44 | 0.130 |
Why?
|
| Referral and Consultation | 2 | 2015 | 142 | 0.130 |
Why?
|
| Stroke | 2 | 2011 | 340 | 0.130 |
Why?
|
| Mass Screening | 2 | 2019 | 541 | 0.130 |
Why?
|
| United States | 9 | 2018 | 5205 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 432 | 0.120 |
Why?
|
| Health Personnel | 1 | 2019 | 277 | 0.120 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2016 | 81 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2015 | 1759 | 0.120 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2013 | 10 | 0.120 |
Why?
|
| Apolipoprotein E4 | 1 | 2016 | 67 | 0.120 |
Why?
|
| China | 1 | 2016 | 229 | 0.120 |
Why?
|
| Substance-Related Disorders | 2 | 2015 | 830 | 0.120 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 609 | 0.120 |
Why?
|
| Psychotherapy, Brief | 1 | 2015 | 17 | 0.110 |
Why?
|
| Patient Dropouts | 1 | 2015 | 32 | 0.110 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2015 | 10 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2016 | 140 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 449 | 0.110 |
Why?
|
| Caloric Restriction | 1 | 2015 | 34 | 0.110 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 310 | 0.110 |
Why?
|
| Prevalence | 5 | 2025 | 1612 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2012 | 1285 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2015 | 156 | 0.100 |
Why?
|
| Phenotype | 3 | 2012 | 780 | 0.100 |
Why?
|
| Cultural Competency | 1 | 2015 | 138 | 0.100 |
Why?
|
| Semicarbazides | 1 | 2013 | 2 | 0.100 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 3156 | 0.100 |
Why?
|
| Hydrazones | 1 | 2013 | 11 | 0.100 |
Why?
|
| Erythrocyte Membrane | 1 | 2013 | 20 | 0.100 |
Why?
|
| Nutrition Surveys | 2 | 2012 | 263 | 0.100 |
Why?
|
| Age Factors | 3 | 2018 | 1154 | 0.100 |
Why?
|
| Iron Chelating Agents | 1 | 2013 | 21 | 0.100 |
Why?
|
| Algorithms | 1 | 2016 | 509 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 31 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 72 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2012 | 206 | 0.100 |
Why?
|
| Adolescent | 7 | 2015 | 6081 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2015 | 359 | 0.100 |
Why?
|
| Mortality | 2 | 2011 | 175 | 0.100 |
Why?
|
| Urban Population | 2 | 2012 | 374 | 0.100 |
Why?
|
| Quality of Life | 1 | 2018 | 616 | 0.100 |
Why?
|
| Job Application | 1 | 2012 | 3 | 0.100 |
Why?
|
| Antimalarials | 1 | 2013 | 64 | 0.100 |
Why?
|
| Personnel Selection | 1 | 2012 | 13 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2012 | 587 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 201 | 0.090 |
Why?
|
| Ophthalmology | 1 | 2012 | 34 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 61 | 0.090 |
Why?
|
| Vitamins | 1 | 2012 | 81 | 0.090 |
Why?
|
| Blood Proteins | 1 | 2012 | 77 | 0.090 |
Why?
|
| Career Choice | 1 | 2012 | 52 | 0.090 |
Why?
|
| Plasmodium falciparum | 1 | 2013 | 144 | 0.090 |
Why?
|
| Introns | 1 | 2012 | 79 | 0.090 |
Why?
|
| Exons | 1 | 2012 | 92 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 82 | 0.090 |
Why?
|
| Cotinine | 1 | 2011 | 44 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2013 | 321 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 638 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2021 | 1600 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 526 | 0.080 |
Why?
|
| Dilatation, Pathologic | 1 | 2009 | 10 | 0.080 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 70 | 0.080 |
Why?
|
| Vasodilation | 1 | 2009 | 64 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2009 | 123 | 0.080 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2009 | 12 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2009 | 135 | 0.080 |
Why?
|
| Medical Staff, Hospital | 1 | 2009 | 15 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2009 | 36 | 0.070 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 236 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2009 | 110 | 0.070 |
Why?
|
| Logistic Models | 1 | 2012 | 1009 | 0.070 |
Why?
|
| Alcoholic Beverages | 1 | 2008 | 16 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2009 | 45 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2009 | 63 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 575 | 0.070 |
Why?
|
| Public Health | 1 | 2012 | 424 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 263 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2007 | 78 | 0.060 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 222 | 0.060 |
Why?
|
| Vitamin B 12 | 1 | 2006 | 23 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2005 | 30 | 0.060 |
Why?
|
| Alleles | 3 | 2016 | 352 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 1 | 2025 | 147 | 0.060 |
Why?
|
| HIV Infections | 1 | 2019 | 2586 | 0.050 |
Why?
|
| Smoking | 1 | 2011 | 1024 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 760 | 0.050 |
Why?
|
| Lipoprotein(a) | 1 | 2004 | 6 | 0.050 |
Why?
|
| Linear Models | 1 | 2005 | 317 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 48 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 1067 | 0.050 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2022 | 4 | 0.050 |
Why?
|
| Cholecystokinin | 1 | 2022 | 16 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2015 | 2544 | 0.050 |
Why?
|
| Mixed Function Oxygenases | 1 | 2002 | 31 | 0.050 |
Why?
|
| Faculty | 1 | 2022 | 105 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 67 | 0.050 |
Why?
|
| Lipids | 1 | 2004 | 256 | 0.050 |
Why?
|
| Mental Recall | 2 | 2012 | 84 | 0.040 |
Why?
|
| Fibrosis | 1 | 2022 | 169 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 98 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 48 | 0.040 |
Why?
|
| Exercise Therapy | 2 | 2016 | 87 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 51 | 0.040 |
Why?
|
| Curriculum | 2 | 2015 | 318 | 0.040 |
Why?
|
| Sex Factors | 2 | 2018 | 1028 | 0.040 |
Why?
|
| Hemolysis | 2 | 2013 | 60 | 0.040 |
Why?
|
| Neoplasms | 1 | 2011 | 1377 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2016 | 760 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2022 | 188 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 1234 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 611 | 0.040 |
Why?
|
| Cathartics | 1 | 2019 | 6 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 1078 | 0.040 |
Why?
|
| Liver | 1 | 2022 | 511 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 108 | 0.040 |
Why?
|
| Stereotyping | 1 | 2019 | 45 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2019 | 81 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2011 | 65 | 0.040 |
Why?
|
| Prejudice | 1 | 2019 | 116 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2022 | 876 | 0.040 |
Why?
|
| Cholesterol, HDL | 2 | 2011 | 99 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 539 | 0.030 |
Why?
|
| Prognosis | 2 | 2013 | 861 | 0.030 |
Why?
|
| Phylogeny | 1 | 2022 | 769 | 0.030 |
Why?
|
| Health Surveys | 1 | 2019 | 405 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 690 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2022 | 1070 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 110 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 1869 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 1596 | 0.030 |
Why?
|
| Comorbidity | 2 | 2009 | 737 | 0.030 |
Why?
|
| Sample Size | 1 | 2015 | 28 | 0.030 |
Why?
|
| Diet, Reducing | 2 | 2005 | 23 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 486 | 0.030 |
Why?
|
| Time Factors | 2 | 2012 | 1857 | 0.030 |
Why?
|
| Breath Tests | 1 | 2013 | 24 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 53 | 0.030 |
Why?
|
| Research Personnel | 1 | 2015 | 206 | 0.030 |
Why?
|
| Hospitals | 1 | 2014 | 117 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 80 | 0.030 |
Why?
|
| Siblings | 1 | 2013 | 22 | 0.030 |
Why?
|
| Communication | 1 | 2015 | 210 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 1092 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 59 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 518 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2012 | 102 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2011 | 34 | 0.020 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 29 | 0.020 |
Why?
|
| Seasons | 1 | 2012 | 139 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 182 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 934 | 0.020 |
Why?
|
| Cultural Diversity | 1 | 2012 | 193 | 0.020 |
Why?
|
| Mice | 1 | 2022 | 6644 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 241 | 0.020 |
Why?
|
| Perception | 1 | 2011 | 215 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 287 | 0.020 |
Why?
|
| Women's Health | 1 | 2010 | 160 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 45 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 76 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2012 | 380 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 54 | 0.020 |
Why?
|
| Awareness | 1 | 2009 | 73 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 115 | 0.020 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2008 | 3 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2008 | 63 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2007 | 7 | 0.020 |
Why?
|
| Hemoglobin, Sickle | 1 | 2007 | 11 | 0.020 |
Why?
|
| Hematocrit | 1 | 2007 | 26 | 0.020 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2007 | 12 | 0.020 |
Why?
|
| Heart Rate | 1 | 2009 | 266 | 0.020 |
Why?
|
| Bilirubin | 1 | 2007 | 18 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 87 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 41 | 0.020 |
Why?
|
| Child | 2 | 2007 | 3443 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 224 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2007 | 64 | 0.020 |
Why?
|
| Death, Sudden | 1 | 2006 | 4 | 0.020 |
Why?
|
| Autopsy | 1 | 2006 | 48 | 0.020 |
Why?
|
| Violence | 1 | 2008 | 136 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2009 | 278 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 1604 | 0.010 |
Why?
|
| Health Promotion | 1 | 2012 | 704 | 0.010 |
Why?
|
| Cause of Death | 1 | 2006 | 186 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2006 | 112 | 0.010 |
Why?
|
| Universities | 1 | 2009 | 559 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 16992 | 0.010 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 42 | 0.010 |
Why?
|
| Lipoproteins, LDL | 1 | 2004 | 67 | 0.010 |
Why?
|
| Triglycerides | 1 | 2004 | 147 | 0.010 |
Why?
|
| Students | 1 | 2009 | 626 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 89 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2002 | 20 | 0.010 |
Why?
|
| Nigeria | 1 | 2002 | 92 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 232 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 92 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 150 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 983 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 2157 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2002 | 430 | 0.010 |
Why?
|